Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1300-1303

  Xicoy, Blanca ^a   Jiménez, María José ^a   García, Olga ^a   Bargay, Joan ^b   Martínez Robles, Violeta ^c   Brunet, Salut ^d   Arilla, María Jesús ^e   Pérez De Oteyza, Jaime ^f   Andreu, Rafael ^g   Casaño, Francisco Javier ^h   Cervero, Carlos Javier ⁱ   Bailén, Alicia ^j   Díez, María ^k   González, Bernardo ^l   Vicente, Ana Isabel ^m   Pedro, Carme ⁿ   Bernal, Teresa ^o   Luño, Elisa ^o   Cedena, María Teresa ^p   Palomera, Luis ^q   Simiele, Adriana ^r   Calvo, José Manuel ^s   Marco, Víctor ^t   Gómez, Eduardo ^u   Gómez, Marta ^v   Gallardo, David ^w   Muñoz, Juan ^x   De Paz, Raquel ^y   Grau, Javier ^a   Ribera, Josep Maria ^a   Benlloch, Luis Enrique ^z   Sanz, Guillermo ^z   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

^c HOSPITAL DE LEÓN   (Spain)

^d Hospital Sant Pau   (Spain)

^e HOSPITAL DE SAGUNTO   (Spain)

^f Sanchinarro Hospital   (Spain)

^g HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ HOSPITAL VIRGEN DE LA LUZ   (Spain)

^j HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l Hepato Bilio Pancreatic Unit   (Spain)

^m HOSPITAL DE LA RIBERA   (Spain)

ⁿ HOSPITAL DEL MAR   (Spain)

^o Hospital de Asturias   (Spain)

^p HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^q Hospital Militär de Zaragoza   (Spain)

^r Epilepsy Unit   (Spain)

^s Hospital de Lanzarote   (Spain)

^t HOSPITAL ARNAU DE VILANOVA   (Spain)

^u Universidad de La Coruña   (Spain)

^v HOSPITAL DE SABADELL   (Spain)

^w HOSPITAL JOSEP TRUETA   (Spain)

^x HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^y HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^z HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

Azacitidine; Elderly; Myelodysplastic syndromes; Response; Safety

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; DISEASE REGISTRY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT RESPONSE; AGE; MORTALITY; MYELODYSPLASTIC SYNDROMES; REGISTER; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; REGISTRIES; TREATMENT OUTCOME;

EID: 84901306598     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.834532     Document Type: Article

References (17)

1. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decisionmaking for older patients wiThhigh-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 2006; 91: 1513-1522. (Pubitemid 44736118
2. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Efficacy of azacitidine compared wiThthat of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: Arandomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
3. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared wiThconventional care regimens in elderly (-/-75 years) patients wiThhigher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; 76: 218-227
4. Fenaux P, Muffti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared wiThconventional care regimens in elderly patients wiThlow bone marrow blast count acute myeloid leukemia. JClin Oncol 2010; 28: 562-569
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classifi cation of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199. (Pubitemid 12073508
6. Swerdlow SH, Campo E, Jaffe E S, editors. W HO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008
7. Greenberg P, Cox C, LeBeau M M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. (Pubitemid 27132124
8. Malcovati L, Germing U, Kuendgen A, et al. Time-Dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. JClin Oncol 2007; 25 : 3503-3510. (Pubitemid 47315575
9. Cheson B D, Greenberg P L, Bennett J M, et al. Clinical application and proposal for modifi cation of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108 : 419-425. (Pubitemid 44061337
10. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958; 53: 457-481
11. Peto R, Pike MC. Conservatism of the approximation © (O-E)2 /E in the log-rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584
12. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients wiThthe myelodysplastic syndrome: A study of the cancer and leukemia group B. JClin Oncol 2002; 20: 2429-2440. (Pubitemid 34525728
13. Fenaux P, Ades L. Review of azacitidine trials in intermediate-2-And high-risk myelodysplastic syndromes. Br J Haematol 2010 ; 149: 244-249
14. Ritchie EK. Safety and Efficacy of azacitidine in the treatment of elderly patients wiThmyelodysplastic syndromes. Clin Interv Aging 2012; 7: 165-173
15. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival wiThimproved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared wiThlow dose ara-C. Br J Haematol 2010; 149 : 244-249
16. Breccia M, Loglisci G, Salaroli A, et al. 5-Azacitidine Efficacy and safety in patients aged-65 years wiThmyelodysplastic syndromes outside clinical trials. Leuk Lymphoma 2012; 53: 1558-1560
17. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients wiThmyelodysplastic syndromes. JClin Oncol 2009; 27: 1850-1856